CADD studies have predicted a number of inhibitors such as linear tripeptides [129], the tubulin binding site of G85R SOD1 [128], resveratrol [130], natural polyphenols of curcumin [131], kaempferol, and kaempferide [132] as potential lead compounds for treating ALS. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.